Pomerantz Law Firm Issues Class Action Alert for Regeneron Pharmaceuticals as Shareholders Face Losses

Investor Alert: Pomerantz Law Firm Takes Action Against Regeneron Pharmaceuticals

In a significant development for investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Pomerantz LLP has announced the initiation of a class action lawsuit. This lawsuit aims to address certain alleged actions by Regeneron and its executives that may have violated securities laws. Investors who have suffered monetary losses due to their investment in Regeneron are encouraged to take immediate action as the court deadlines approach.

Understanding the Lawsuit

The current class action was initiated as a result of concerns around securities fraud and unlawful business practices reportedly committed by Regeneron and its management team. Specifically, the lawsuit addresses communications surrounding the Phase III Fianlimab-Libtayo Study. In a call on April 29, 2026, Regeneron disclosed changes made to this study, which extended the pool of patients eligible for progression-free survival analysis. Following this disclosure, Regeneron’s stock price fell significantly, highlighting the direct economic ramifications of the information revealed to the investors.

Further compounding these issues, Regeneron announced on May 15, 2026, that the Phase 3 Trial of Fianlimab did not meet statistical significance for its primary endpoint. Consequently, the company's stock price dropped sharply once more. These sequences of events raised questions among investors regarding the integrity of the Company’s disclosures and adherence to proper securities regulations.

Investor Participation and Legal Representation

It’s critical for any investor who acquired Regeneron securities during the Class Period to take action swiftly. Interested parties have until September 14, 2026, to petition the court to be appointed as Lead Plaintiff for the class. Additionally, those who wish to participate in the lawsuit and advocate for their rights can obtain a copy of the Complaint by visiting Pomerantz Law Firm's website.

To assist investors, Pomerantz LLP has made provisions for inquiries through legal representatives. Individuals can reach out to Danielle Peyton via email at [email protected] or by calling 646-581-9980. When reaching out, it is advisable to include your mailing address, phone number, and the number of shares purchased. Such details will facilitate a thorough investigation into individual cases and better representation in court.

Pomerantz Law Firm’s Reputation

Pomerantz LLP, with offices situated in major cities including New York, Chicago, and Los Angeles, has established itself as a preeminent law firm specializing in corporate, securities, and antitrust class litigation. The firm, founded by Abraham L. Pomerantz, has been a proactive advocate for investors’ rights for over 85 years, recouping numerous multimillion-dollar awards in similar cases.

Conclusion

For investors in Regeneron Pharmaceuticals, the initiation of this class action lawsuit serves as a crucial reminder to stay vigilant about corporate actions and their potential impacts on your investment portfolio. Joining this lawsuit could be a critical step towards seeking justice for losses experienced due to the alleged misconduct of the Company. Immediate action is advised to ensure that your voice is heard in this pivotal legal affair.